Medical treatment of osteoporosis - Increasing options

被引:0
作者
Leong, KH [1 ]
机构
[1] 04 18 Gleneagles Med Ctr, Singapore 258499, Singapore
关键词
bisphosphonates; calcitonin; fracture risk; hormone replacement therapy; parathyroid hormone; selective oestrogen receptor modulators;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Many drugs are now available for the prevention and treatment of osteoporosis. They have differing levels of evidence of efficacy and each may be used according to clinical indications. Methods: A Medline search of clinical drug trials using various therapeutic agents used for osteoporosis was carried out. Results: Several randomised controlled trials have been carried out using many agents. The agents with the best data to date with regards to the prevention of spine as well as hip fractures in patients with prevalent fractures belong to alendronate and risedronate. Parathyroid hormone has been shown in one trial to reduce the risk of non-vertebral fractures. For reduction of spine fractures, in addition to the above two bisphosphonates, many agents, in particular raloxifene, have been shown to be clearly beneficial. Weaker data exist for hormone replacement, calcitonin, cyclical etidronate and the vitamin D analogues calcitriol and alfacalcidol Conclusion: There are many therapeutic agents shown to be clearly effective in the treatment of osteoporosis.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 56 条
  • [1] Adachi JD, 2000, J RHEUMATOL, V27, P2424
  • [2] Adachi JD, 2001, ARTHRITIS RHEUM-US, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO
  • [3] 2-W
  • [4] THE PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS WITH NANDROLONE DECANOATE
    ADAMI, S
    FOSSALUZZA, V
    ROSSINI, M
    BERTOLDO, F
    GATTI, D
    ZAMBERLAN, N
    LOCASCIO, V
    [J]. BONE AND MINERAL, 1991, 15 (01): : 72 - 81
  • [5] Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures
    Anderson, FH
    Francis, RM
    Bishop, JC
    Rawlings, DJ
    [J]. AGE AND AGEING, 1997, 26 (05) : 359 - 365
  • [6] Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption
    Anderson, FH
    Francis, RM
    Peaston, RT
    Wastell, HJ
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (03) : 472 - 478
  • [7] How well are community-living women treated for osteoporosis after hip fracture?
    Bellantonio, S
    Fortinsky, R
    Prestwood, K
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (09) : 1197 - 1204
  • [8] Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
    Black, DM
    Thompson, DE
    Bauer, DC
    Ensrud, K
    Musliner, T
    Hochberg, MC
    Nevitt, MC
    Suryawanshi, S
    Cummings, SR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) : 4118 - 4124
  • [9] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    Black, DM
    Cummings, SR
    Karpf, DB
    Cauley, JA
    Thompson, DE
    Nevitt, MC
    Bauer, DC
    Genant, HK
    Haskell, WL
    Marcus, R
    Ott, SM
    Torner, JC
    Quandt, SA
    Reiss, TF
    Ensrud, KE
    [J]. LANCET, 1996, 348 (9041) : 1535 - 1541
  • [10] Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496